Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic Ulcers

Lambìase, Alessandro; Rama, Paolo; Bombardieri, Stefano; Caprioglio, Giancarlo; Aloe, Luigi

doi:10.1056/nejm199804233381702

Cited by 367 publications

(242 citation statements)

References 29 publications

Supporting

Mentioning

226

Contrasting

Unclassified

Order By: Relevance

“…Intracerebral administration of NGF has been shown to be beneficial in Parkinson's and Alzheimer's patients (10)(11)(12), and intraocular administration of NGF in animal models has been shown to inhibit RGC degeneration after mechanical, ischemic or hypertensive injury (13)(14)(15). NGF applied topically to the eye has also been shown to restore sensory nerve function to the ocular surface of patients with neurotrophic keratitis (16). Interestingly, absorption studies have demonstrated that topical ocular NGF reaches the retina, optic nerve, and brain in animals (17,18).…”

mentioning

confidence: 99%

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma

Lambìase¹,

Aloe

Centofanti

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

205

162

View full text Add to dashboard Cite

Elevated intraocular pressure (IOP) in glaucoma causes loss of retinal ganglion cells (RGCs) and damage to the optic nerve. Although IOP is controlled pharmacologically, no treatment is available to restore retinal and optic nerve function. We evaluated the effects of NGF eye drops in a rat model of glaucoma. We also treated 3 patients with progressive visual field defects despite IOP control. Glaucoma was induced in rats through injection of hypertonic saline into the episcleral vein. Initially, 2 doses of NGF (100 and 200 g/mL) were tested on 24 rats, and the higher dose was found to be more effective. NGF ͉ optic nerve ͉ retina

show abstract

mentioning

confidence: 99%

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma

Lambìase¹,

Aloe

Centofanti

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

205

162

View full text Add to dashboard Cite

show abstract

“…52,53 In an open uncontrolled study, topical nerve growth factor NGF treatment induced corneal healing in 43 patients affected by moderate and severe neurotrophic keratitis (stages 2 and 3). 19,20 Restoration of corneal integrity was associated with recovery of corneal sensitivity in most of the patients. Topical treatment with NGF represents a promising therapy to prevent the onset and progression of neurotrophic keratitis.…”

Section: Future Developments and Conclusionmentioning

confidence: 97%

“…18 We have recently evaluated the potential role of nerve growth factor (NGF) in the treatment of neurotrophic keratitis. 19,20 NGF induces in vitro and in vivo recovery of sensory neurons and induces the production of Ach in the central nervous system and SP in the peripheral nervous system. 21,22 In addition, NGF plays an important role in the balance between sensory and sympathetic innervation, by modulating their functions.…”

Section: Pathophysiologymentioning

confidence: 99%

“…25 In our study, in 43 patients affected by neurotrophic ulcers, topical administration of NGF restored corneal integrity and improved corneal sensitivity. 19,20 To summarize, corneal sensory nerve damage induces marked changes in the levels of neuromediators that lead to an impairment of epithelial cell vitalityFclinically represented by the development of recurrent or persistent epithelial defects.…”

Section: Pathophysiologymentioning

confidence: 99%

See 1 more Smart Citation

Neurotrophic keratitis

Bombardieri

Rama²,

Olzi³

et al. 2003

Eye

323

366

View full text Add to dashboard Cite

Neurotrophic keratopathy is a degenerative corneal disease induced by an impairment of trigeminal nerve. Impairment of loss of corneal sensory innervation is responsible for corneal epithelial defects, ulcer, and perforation. In the present report, we reviewed the pathogenesis, diagnosis, and therapeutic aspects of this disease. An accurate history and clinical examination, including the function of cranial nerves, together with the clinical features of the ocular surface are essential for a prompt diagnosis. The evaluation of the corneal sensitivity and tear film function are important diagnostic steps as well. Specific medical and surgical treatments, based on the clinical staging of the disease, are often able to halt its progression. Future developments in the medical treatment including the administration of neuropeptide and growth factors are presented.

show abstract

“…Several therapeutic strategies for delivery of NGF in animal models and in human diseases have been explored and clinical steps have been attempted, while others are currently in progress to evaluate whether NGF and/or TrkA receptor agonists can prevent or protect against cell degeneration in the nervous system, visual system, cutaneous and myocardial tissue (14,15,19,(22)(23)(24)(25)(26)(27)(28). It most likely exerts therapeutic effects on cardiometabolic diseases such as atherosclerosis, obesity, type 2 diabetes and metabolic syndrome (29)(30)(31).…”

Section: Ngf-ome or The Multiple Life Of Ngfmentioning

confidence: 99%

Rita Levi-Montalcini: Presence in The Absence

Aloe

Chaldakov

2013

Balkan Med J

Self Cite

View full text Add to dashboard Cite

At the end of the 19 th century, it was envisaged by Santiago Ramon y Cajal, but not, proven, that life at the neuronal level requires trophic support. The proof was obtained in the early 1950's by work initiated by Rita Levi-Montalcini (RLM) discovering the nerve growth factor (NGF). Today, NGF and its relatives, collectively designated neurotrophins, are well recognized as mediators of multiple biological phenomena in health and disease, ranging from the neurotrophic through immunotrophic and epitheliotrophic to metabotrophic effects. Consequently, NGF and other neurotrophins are implicated in the pathogenesis of a large spectrum of neuronal and non-neuronal diseases, from Alzheimer's and other neurodegenerative diseases to atherosclerosis and other cardiometabolic diseases. Recent studies demonstrated the therapeutic potentials of NGF in these diseases, including ocular and cutaneous diseases. Furthermore, NGF TrkA receptor antagonists emerged as novel drugs for pain, prostate and breast cancer, melanoma, and urinary bladder syndromes. Altogether, NGF's multiple potential in health and disease is briefly described here.

show abstract

Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic Ulcers

Abstract: In this preliminary, uncontrolled study, topically applied exogenous nerve growth factor restored corneal integrity in patients with corneal neurotrophic ulcers.

Cited by 367 publications

References 29 publications

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma

Neurotrophic keratitis

Rita Levi-Montalcini: Presence in The Absence

Contact Info

Product

Resources

About